Neurocrine Biosciences
NBIX
#1550
Rank
NZ$23.39 B
Marketcap
NZ$234.62
Share price
2.37%
Change (1 day)
-11.54%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): NZ$1.00 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$2.68 Billion. In 2024 the company made an earning of NZ$1.01 Billion, an increase over its 2023 earnings that were of NZ$0.51 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.00 B-1.44%
2024 NZ$1.01 B96.41%
2023 NZ$0.51 B41.13%
2022 NZ$0.36 B73.74%
2021 NZ$0.21 B-8.82%
2020 NZ$0.23 B77.78%
2019 NZ$0.13 B49.83%
2018 NZ$87.01 M-142.57%
2017 -NZ$0.21 Billion-14.73%
2016 -NZ$0.24 Billion53.15%
2015 -NZ$0.16 Billion46.25%
2014 -NZ$0.11 Billion29.66%
2013 -NZ$82.55 Million-3530.8%
2012 NZ$2.4 M-95.73%
2011 NZ$56.36 M
2009 -NZ$79.24 Million-45.38%
2008 -NZ$0.15 Billion-58.87%
2007 -NZ$0.36 Billion87.3%
2006 -NZ$0.19 Billion351.97%
2005 -NZ$41.66 Million-52.09%
2004 -NZ$86.96 Million-10.98%
2003 -NZ$97.69 Million
2001 -NZ$72.92 Million
1999 -NZ$32.89 Million108.32%
1998 -NZ$15.79 Million
1996 NZ$4.81 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$19.69 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.75 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$37.39 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$43.43 M-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$69.4 Million-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$83.99 M-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-NZ$7.97 Million-100.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.62 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK